GC
AXSM icon

Grimes & Company’s Axsome Therapeutics AXSM Stock Holding History

Grimes & Company’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$315K Buy
1,287
+2
+0.2% +$434 0.01% 371
2026
Q1 		$217K Sell
1,285
-175
-12% -$30.2K 0.01% 401
2025
Q4 		$267K Buy
+1,460
New +$204K 0.01% 398

Other funds holding AXSM

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
BWP
Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
PCM
Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
TAM
Tealwood Asset Management Minneapolis, Minnesota $261M AUM 52.68% 1-Year Est. Return
CA
Cannon Advisors Charlotte, North Carolina $164M AUM 30.34% 1-Year Est. Return
MCP
Mirador Capital Partners Pleasanton, California $817M AUM 42.46% 1-Year Est. Return

Grimes & Company's AXSM Position: Q2 2026 in Review

Grimes & Company increased its Axsome Therapeutics (AXSM) stake by 0.16% in Q2 2026, buying an estimated $434 and bringing the position to 1,287 shares worth $315K. The position accounts for 0.01% of the portfolio, ranked #371.

Grimes & Company first reported a position in AXSM in Q4 2025 and has held it in 3 quarters since. 43 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Grimes & Company held 1,287 shares of Axsome Therapeutics worth $315K as of Q2 2026.
  • Grimes & Company bought 2 Axsome Therapeutics shares in Q2 2026, an estimated $434.
  • Axsome Therapeutics made up 0.01% of Grimes & Company's portfolio in Q2 2026, its #371 holding.
  • Grimes & Company first reported a position in Axsome Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 43 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Grimes & Company's 13F filing for Q2 2026, filed 17 Jul 2026.